Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo

Ultrastructural Pathology

Volumn 23, Issue 2, 1999, Pages 107-126

  Herrera, Guillermo A ^a   Russell, William J ^a   Isaac, Jorge ^a   Turbat Herrera, Elba A ^a,b   Tagouri, Yahia M ^c   Sanders, Paul W ^d   Picken, Maria M ^e   Dempsey, Susanna ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Department of Internal Medicine   (United States)

^c St Mary's Hospital   (United States)

^d University of Alabama at Birmingham   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amyloid; Light chains; Mesangium; Metalloproteases; Myeloma; Ultrastructure

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; IMMUNOGLOBULIN LIGHT CHAIN; LAMININ; MATRIGEL; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

AMYLOID; AMYLOIDOSIS; AUTOIMMUNE DISEASES; CELLS, CULTURED; COLLAGENASES; EXTRACELLULAR MATRIX; GLOMERULAR MESANGIUM; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICROSCOPY, FLUORESCENCE;

EID: 0032939741     PISSN: 01913123     EISSN: None     Source Type: Journal    
DOI: 10.1080/019131299281752     Document Type: Article

References (73)

1. 1. Kashgarian M, Mesangium and glomerular disease. Lab Invest. 1985;52:569-571.
2. 2. Rosenblum ND. The mesangial matrix in the normal and sclerotic glomerulus. Kidney Int. 1994;S45:S73-S77.
3. 3. Couchman JR, Beavan LA, McCarthy KJ. Glomerular matrix: synthesis, turnover and role in mesangial expansion. Kidney Int. 1994;45:328-225.
4. 4. Abboud HE. Mesangial cells in glomerular injury. Nephrology. 1991;11:299-306.
5. 5. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulator of growth factor activities. Cell. 1991;64:867-869.
6. 6. Roberts AB, McCune BK, Sporn MB. TGF-β: regulation of extracellular matrix. Kidney Int. 1992;41:557-559.
7. 7. Morel-Maroger Striker L, Killen PD, Chi E, Striker GE. The composition of glomerulosclerosis, 1: studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest. 1984;51:181-192.
8. 8. Sanders PW, Herrera GA. Monoclonal immunoglobulin light-chain-related renal diseases. Semin Nephrol. 1993;13:324-341.
9. 9. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH. The spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest. 1991;64:527-537.
10. 10. Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest. 1993;92:2975-2983.
11. 11. Huang Z-O, Kirk KA, Connelly KG, Sanders PW. Human Bence Jones protein bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Invest. 1993;92:1975-2983.
12. 12. Harper PA, Robinson JM, Hoover RL, Wright TC, Karnovsky MJ. Improved methods for culturing rat glomerular cells. Kidney Int. 1984;26:875-880.
13. 13. Kisilevsky R, Boudreau L. Kinetics of amyloid deposition, 1: the effects of amyloid enhancing factor and splenectomy. Lab Invest. 1983;48:53-59.
14. 14. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. Histochem Cytochem. 1962;110:355-364.
15. 15. Mowry RW, Rodenbough JW, Megginson AG. Detection of amyloid in pancreatic islets of diabetics by thioflavine-T fluorescence and its comparison with traditional stains for amyloid (abstract). Am J Pathol. 1963;43:38.
16. 16. Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
17. 17. Valenzuela R, Deodhar SD. Tissue immunofluorescence. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology, 3rd. ed. Washington, DC: American Society for Microbiology; 1986:923-926.
18. 18. Herrera GA, Sanders PW, Reddy BV, Hasbargen JA, Hammond WS, Brooke JD. Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain related renal diseases. Ultrastruct Pathol. 1994;18:401-416.
19. 19. Martin J, Davies M, Thomas G, Lovett DH. Human mesangial cells secrete a GBM-degrading neutral proteinase and a specific inhibitor. Kidney Int. 1989;36:790-801.
20. 20. Tagouri YM, Sanders PW, Picken MM, Siegal GP, Kerby JD, Herrera GA. In vitro AL-amyloid formation by rat and human mesangial cells. Lab Invest. 1996;74:290-302.
21. 21. Isaac J, Kerby JD, Russell W, Dempsey S, Sanders PW, Herrera GA. In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid Int J Clin Invest. 1998;5:238-246.
22. 22. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang Z-O, Sanders PW. Pathogenesis of glomerulosclerosis in light chain deposition disease: role for transforming growth factor. Am J Pathol. 1995;147:375-385.
23. 23. Herrera GA. Low molecular proteins and the kidney: physiologic and pathologic considerations. Ultrastruct Pathol. 1994;18:89-98.
24. 24. Bruneval P, Foidart JM, Nochy D, Camilleri JP, Bariety J. Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus. Hum Pathol. 1985;16:477-484.
25. 25. Turbat-Herrera EA, Isaac J, Sanders PW, Truong LD, Herrera GA. Integrated expression of glomerular extracellular matrix proteins and β1 integrins in monoclonal light chain-related renal diseases. Mod Pathol. 1997;10:485-495.
26. 26. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Eng J Med. 1991;324:1845-1851.
27. 27. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest. 1992;90:1-7.
28. 28. Border W, Okuda S, Nakamura T. Extracellular matrix and glomerular disease. Semin Nephrol. 1989;9:307-317.
29. 29. Broeckelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA. 1991;88:6642-6646.
30. 30. Raghow B, Irish P, Kang AH. Coordinate regulation of transforming growth factor β gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. J Clin Invest. 1989;84:1836-1842.
31. 31. Castilia A, Prieto J, Fausto N. Transforming growth factor β1 and alpha in chronic liver disease. N Engl J Med. 1991;324:933-940.
32. 32. Thompson NL, Basoberry EH, Speir W, et al. Transforming growth factor beta-1 in acute myocardial infarct in rats. Growth Factors. 1988;1:91-99.
33. 33. Shah MD, Foreman M, Ferguson WJ. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor β Lancet. 1992;339:213-214.
34. 34. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest. 1996;74:991-1003.
35. 35. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (London). 1992;360:361-364.
36. 36. Herrera GA, Shultz J, Soong S, Sanders PW. Growth factors in monoclonal light chain-related renal diseases. Hum Pathol. 1994;25:883-892.
37. 37. Mignatti P. Extracellular matrix remodelling by metalloproteinases and plasminogen activators. Kidney Int. 1995;47:S12-S14.
38. 38. Turck J, Pollock AS, Lovett DH. Gelatinase A in a glomerular mesangial cell growth and differentiation factor. Kidney Int. 1997;51:1397-1400.
39. 39. Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover. Kidney Int. 1992;41:671-678.
40. 40. Truong L, Pindur J, Barrios R, et al. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int. 1994;45:201-210.
41. 41. Truong LD, Pindur J, Foster S, Majesky M, Suki WN. Tenascin expression in nephrogenesis and in normal or pathologic glomerulus: morphologic features and functional implications. Nephron. 1996;72:499-506.
42. 42. Truong LD, Majesky MW, Pindur J. Tenascin in synthesized and secreted by rat mesangial cells in culture and is present in extracellular matrix in human glomerular disease. J Am Soc Nephrol. 1994;4:1771-1777.
43. 43. Ishimura E, Bernd Sterzel R, Budde K, Kashgarian M. Formation of extracellular matrix by cultured rat mesangial cells. Am J Pathol. 1989;134:843-855.
44. 44. Jyo Y, Sasaki T, Nomura S et al. Expression of tenascin in mesangial injury in experimental glomerulonephritis. Exp Nephrol. 1997;5:423-428.
45. 45. Sakamura T, Kusano I. Tenascin in tissue perturbation repair. Acta Pathol Jpn. 1991;41:247-258.
46. 46. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin and thrombospondin in pulmonary fibrosis. Am J Pathol. 1995;147:1759-1769.
47. 47. Masaki T, Yorioka N, Taniguchi Y, et al. Role of tenascin in human immunoglobulin A nephropathy. J Intern Med Res. 1997;25:247-254.
48. 48. Imai K, Kausakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994;352:216-218.
49. 49. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev. 1992;6:1821-1831.
50. 50. Adams-Pearson C, Pearson D, Shibahara S, Hotsteenge J, Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-β. EMBO J. 1988;7:2977-2982.
51. 51. Marti H-P, McNeil L, Thomas G, Davies M, Lovett DH. Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1. Biochem J. 1992;285:899-905.
52. 52. Marti H-P, McNeil L, Davies M, Martin J, Lovett DH. Homology cloning of rat 72 kDa type IV collagenase: cytokine and second-messenger inducibility by glomerular mesangial cells. Biochem J. 1993;291:441-446.
53. 53. He C-J, Yang C-W, Peten EP, et al. Collagen and collagenase mRNAs in normal and sclerotic glomeruli: predictors of progression and response to therapy. Kidney Int. 1997;47(349):S39-S43.
54. 54. Baricos WH, Shah SV. Proteolytic enzymes as mediators of glomerular injury. Kidney Int. 1991;40:161-173.
55. 55. Carome MA, Striker LJ, Peten EP, et al. Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am J Physiol. 1993;264:F923-F929.
56. 56. Heidland A, Sebekova K, Paczek L, Teschner M, Dammrich J, Gaciong Z. Renal fibrosis: role of impaired proteolysis and potential therapeutic strategies. Kidney Int. 1997;S62:S32-S35.
57. 57. Kisilevsky R, Gruys E, Shirahama T. Does amyloid enhancing factor exist? Is AEF a single biological entity? Amyloid Int J Clin Invest. 1995;2:128-133.
58. 58. Brown PD, Kleiner DE, Unsworth EJ, Stetler-Stevenson WG. Cellular activation of the 72 kDa type of procollagenase/TIMP-2 complex. Kidney Int. 1993;43:163-170.
59. 59. Brinckerhoff CE, Mitchell TI, Klarmilowicz MJ, Kluve-Beckerman B, Benson MD. Autocrine induction of collagenase by serum amyloid A-like and β2-microglobulin-like proteins. Science. 1995;243:655-657.
60. 60. Zhu L, Herrera GA, White CR, Sanders PW. Immunoglobulin light chain alters mesangial cell calcium homeostasis. Am J Physiol. 1997;272 (Renal Physiol. 41):F319-F324.
61. 61. Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A. Preferential expression of human lambda-light chain variable region subgroups in multiple myeloma, AL-amyloidosis and Waldenstrom macroglobulinemia. Clin Immunopathol. 1994;71:183-189.
62. 62. Helms LR, Wetzel R. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis. J Mol Biol. 1996;257:77-86.
63. 63. Stevens FJ, Myatt EA, Chang C-H, et al. A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry. 1995;34:10697-10702.
64. 64. Decourt C, Cogne M, Rocca A. Structural peculiarities of a truncated VκIII immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol. 1996;1106:357-361.
65. 65. Decourt C, Touchard G, Preud'homme J-L, et al. Complete primary sequences of two lambda immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease. Am J Pathol. 1998;153:313-318.
66. 66. Khamlichi AA, Rocca A, Touchard G, Aucouturier P, Preud'homme JL, Cogne M. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood. 1995;86:3655-3659.
67. 67. Denoroy L, Deret S, Aucouturier P. Overrepresentation of the VκIV subgroup in light chain deposition disease. Immunol Lett. 1994;42:63-66.
68. 68. Gallo G, Goni F, Boctor F, et al. Light chain cardiomyopathy: structural analysis of the light chain deposits. Am J Pathol. 1996;148:1397-1406.
69. 69. Belloti V, Stoppini M, Merlini G, et al. Amino acid sequence of κ Sci, the Bence Jones protein isolated from a patiant with light chain deposition disease. Biochim Biophys Acta. 1991;1097:177-182.
70. 70. Klamlichi AA, Aucoutrier P, Silvain C, et al. Primary structure of a variable region of the VκI subgroup(ISE) in light chain deposition disease. Clin Exp Immunol. 1993;91:506-509.
71. 71. Belloti V, Stoppini M, Magione PM, et al. Structural and functional characterization of three human immunoglobulin κ light chains with different pathological implications. Biochim Biophys Acta. 1996;1317:161-167.
72. 72. Schorman N, Murrell JR, Lipnieks JJ, Benson MD. Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc Natl Acad Sci USA. 1995;92:9490-9494.
73. 73. Khamlichi AA, Aucouturier P, Silvain C, et al. Primary structure of a monoclonal κ chain in myeloma with light chain deposition disease. Clin Exp Immunol. 1992;87:122-126.